The proportion of patients treated with NACT has increased over time, from 13 (8.3%) in 2016 to 28 (14.2%) in 2021, in line with international trends.46 Currently, systemic treatment is customized according to each breast cancer subtype and has moved toward NACT rather than adjuvant chemotherapy.47 The highest use of NACT was in HER2-enriched and TNBC in approximately 44% of the patients, whereas luminal types constituted 55.7% of the patients. The gene discussed is ERBB2; the disease is breast carcinoma.